Neutral
Y Intercept Hong Kong Ltd has made a significant investment in Moderna, Inc. (NASDAQ:MRNA), purchasing 460,853 shares valued at approximately $13.59 m...
Neutral
This article provides a financial overview of Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs (BCBA:MRNA.CI), specifically focusing on its a...
Neutral
WINTON GROUP Ltd initiated a new position in Moderna, Inc. by purchasing 27,144 shares valued at $800,000 during the fourth quarter. This move highlig...
Neutral
Letko Brosseau & Associates Inc. significantly reduced its stake in Moderna (NASDAQ:MRNA) by 20.5% in the fourth quarter, selling 186,950 shares. Desp...
Neutral
Norges Bank has acquired a new position in Moderna, Inc. (NASDAQ:MRNA) by purchasing 2,702,832 shares valued at approximately $79.71 million in the fo...
This SEC filing (Form 144) for Moderna, Inc. (MRNA) indicates a proposed sale of 3471 shares by an individual. The shares were acquired through a stoc...
Bullish
UBS raised its price target for Moderna, Inc. (MRNA) to $45 from $36, maintaining a Neutral rating, due to significant upcoming pipeline developments....
Neutral
Moderna, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, scheduled for Tuesday, June 9th at 3:20 ...
Bullish
Moderna's personalized cancer vaccine, intismeran autogene, combined with Merck’s Keytruda, substantially reduced recurrence or death risk in advanced...
Moderna (Nasdaq: MRNA) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, at 3:20 p.m. E...
Bullish
Moderna has received $50 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the Bundibugyo strain of Ebo...
Bullish
Moderna has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine targeting the Bundibugyo ebolavirus (BDBV) ...
Bullish
Moderna has expanded its collaboration with CEPI, securing up to $50 million to advance a potential vaccine against Bundibugyo ebolavirus (BDBV). This...
Bullish
Moderna has enhanced its partnership with CEPI to develop a vaccine against the Bundibugyo ebolavirus, which currently lacks an approved vaccine. CEPI...
Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their collaboration to develop a potential vaccine against Bundib...
Neutral
Legal & General Group Plc reduced its stake in Moderna, Inc. (MRNA) by 6.4% in the fourth quarter of the previous year, selling 64,289 shares and reta...
Bullish
Moderna and CEPI have expanded their collaboration to develop a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola for which no ...
Bullish
Moderna and CEPI have expanded their collaboration to develop a vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which...
Moderna and CEPI have expanded their collaboration to advance a potential vaccine against the Bundibugyo ebolavirus (BDBV), with CEPI committing up to...
Bearish
Jefferies Financial Group Inc. significantly reduced its stake in Moderna by selling 49,596 shares, decreasing its holdings by 52.1% in the fourth qua...